2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5883 Humanized CD19/CD20 dual-targeting CAR-T cells generated in vivo by a novel fusogen-enabled lentiviral vector (QI-019E) outperform single-target cars and show a favorable safety profile in preclinical lymphoma models

xiaoyu meng, xiaoling wang2, yixuan zhou3, Jiapan Hu4, tianying chen5, Zhenkun wang6, ying chen7, xiaomeng Bian8, Yingyong Xu, MD, PhD, MBA9, zhenzhen wang10, xiaobin song11, nian chen12, Heng Mei, MD, PhD13, george church14, Luhan Yang, PhD15
1 Qihan Biotechnology, Hangzhou, China
2 Qihan Biotechnology, Hangzhou, China
3 Qihan Biotechnology, Hangzhou, China
4 Qihan Biotechnology, Hangzhou, China
5 Qihan Biotechnology, Hangzhou, China
6 Qihan Biotechnology, Hangzhou, China
7 Qihan Biotechnology, Hangzhou, China
8 Qihan Biotechnology, Hangzhou, China
9 Qihan Biotechnology, Hangzhou, China
10 Qihan Biotechnology, Hangzhou, China
11 Qihan Biotechnology, Hangzhou, China
12 Qihan Biotechnology, Hangzhou, China
13 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, wuhan, China
14 Department of Genetics, Harvard Medical School, boston, United States
15 Qihan Biotechnology, Hangzhou, China

Background Lentiviral vector–mediated in vivo generation of CAR-T cells represents a transformative approach in cellular immunotherapy, eliminating the need for apheresis, ex vivo manufacturing, and lymphodepletion. However, two barriers still limit this approach. First, conventional viral envelopes trigger premature T-cell activation, causing excessive cytokine release and functional exhaustion. Second, CD19-directed therapy is limited by antigen escape, and murine-derived scFvs elicit anti-CAR humoral and cellular immunity that shortens persistence This humoral and cellular immunity becomes a particularly consequential liability for in vivo–generated CAR-T cells, which are produced continuously in an immunocompetent host without the lymphodepletion commonly applied to mitigate rejection in ex vivo CAR-T settings. QI-019E is a third-generation lentiviral vector pseudotyped with a proprietary engineered fusogen and a CD3-specific binder for T cell–restricted transduction, encoding a fully humanized CD19/CD20 dual-targeting CAR. Because CD19 and CD20 differ in expression across B-cell differentiation stages and are heterogeneously expressed within individual lymphomas, dual targeting is designed to cover tumor subpopulations missed by either antigen alone.

Methods QI-019E was produced as a third-generation lentiviral vector pseudotyped with a novel fusogen variant coupled to a CD3-specific scFv for targeted T-cell entry. The transgene encodes a bispecific CAR comprising humanized anti-CD19 and anti-CD20 binders. Transduction efficiency and activation dynamics were assessed in primary human T cells (CD69/CD25, cytokine profiling). Immunogenicity of the humanized construct was evaluated relative to murine-derived counterparts using in silico T-cell epitope prediction and in vitro assays of donor PBMC reactivity to CAR-expressing cells. Antitumor activity was compared head-to-head against CD19-only and CD20-only CAR constructs delivered by the same vector backbone, using serial antigen-rechallenge killing assays and mixed CD19?CD20? / CD19?CD20? / CD19?CD20? tumor models. In vivo efficacy and safety were evaluated in humanized mice bearing established Raji or Daudi xenografts, with tumor burden, CAR-T expansion, persistence, and systemic cytokines assessed serially.

Results Transduction without premature activation. QI-019E achieved high-titer, CD3-dependant transduction of primary human T cells with minimal induction of CD69/CD25 and near-baseline IFN-γ, defining a functionally silent entry phenotype that preserves T-cell quiescence until antigen engagement.

Dual targeting outperforms single targeting. In serial rechallenge assays, dual CD19/CD20 CAR-T cells sustained cytotoxicity across multiple rounds against Raji and Daudi, whereas single-target constructs showed progressive loss of killing. In antigen-heterogeneous and antigen-loss models, CD19-only and CD20-only CAR-T cells permitted outgrowth of the corresponding antigen-negative subpopulation, while QI-019E cleared all subpopulations and prevented escape. In vivo, a single intravenous dose of QI-019E produced complete tumor clearance with greater depth and durability than either single-target vector at matched doses.

Humanized binders reduce immunogenicity. The humanized CD19 and CD20 binders showed markedly reduced predicted T-cell epitope burden and lower allogeneic PBMC reactivity than murine-derived comparators, supporting reduced risk of anti-CAR rejection and improved persistence of in vivo–generated CAR-T cells.

Favorable safety. No measurable cytokine release syndrome, off-target transduction, or organ toxicity was observed, consistent with the optimized binder–fusogen configuration.

Conclusions QI-019E is a fusogen-enabled lentiviral vector that generates humanized CD19/CD20 dual-targeting CAR-T cells directly in vivo, decoupling viral entry from premature T-cell activation. Dual targeting conferred superior and more durable tumor control than single-target CARs by covering antigen-heterogeneous and antigen-loss subpopulations, and humanization mitigated anti-CAR immunogenicity — a distinct advantage for continuously generated in vivo CAR-T cells. These data support advancing QI-019E as a single-infusion, off-the-shelf in vivo CAR-T therapy for relapsed/refractory B-cell lymphoma.

Luhan Yang, PhD: No relevant conflicts of interest to declare.